PRRT2 and breast carcinoma: Similarly, our nPKC-θ-specific inhibitor reduced high nuclear accumulation of PKC-θ and global phosphorylation of H2Bser32 in mesenchymal phenotype-induced breast cancer cells to greater extent than the catalytic inhibitor C27.